Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Optomed

3.985

 

EUR

 

-1.12 %

5,461 following

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Investor consensus

Optomed is a medical technology company. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that is resold under different brands. The company operates worldwide, with the largest presence in the Nordic market. The customers consist of research institutes and hospitals. Optomed is headquartered in Oulu.

Read more
Market cap
78.48M EUR
Turnover
38.9K EUR
P/E (adj.) (25e)
-15.07
EV/EBIT (adj.) (25e)
-16.5
P/B (25e)
4.15
EV/S (25e)
4.36
Dividend yield-% (25e)
-
Coverage
Recommendation
Accumulate
Target price
5.20 EUR
Updated
07.05.2025
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
7.8
2025

Interim report Q2'25

6.11
2025

Interim report Q3'25

Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types
Press release6/5/2025, 7:30 AM

Optomed Oyj: Optomed Launches Next-Generation Handheld Fundus Camera to Power the Future of Oculomics in Everyday Healthcare

Optomed
Regulatory press release5/9/2025, 6:30 PM

Optomed Oyj: Decisions of the Organization Meeting of Optomed's Board of Directors

Optomed
Regulatory press release5/9/2025, 11:00 AM

Optomed Oyj: Decisions of the Annual General Meeting

Optomed

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/9/2025, 10:40 AM

Optomed Oyj: Correction to the pdf-version of Optomed's Annual Report

Optomed
Press release5/7/2025, 9:56 AM

Redeye: Optomed Q1 - A solid start to the year

Optomed
Regulatory press release5/6/2025, 6:00 AM

Optomed Oyj: Optomed Plc: Interim Report, January - March 2025

Optomed
Analyst Comment4/4/2025, 1:23 PM by
Juha Kinnunen, Atte Riikola, Thomas Westerholm, Pauli Lohi, Rauli Juva, Aapeli Pursimo, Antti Viljakainen

Case: Potential impacts of U.S. import tariffs on Helsinki Stock Exchange companies

The new import duties announced by the United States are causing headaches for several companies on the Helsinki Stock Exchange, in addition to generally weakening the global economic outlook and increasing uncertainty. Under the current US administration, situations can change rapidly, but according to the current plan, the tariffs should come into effect next Wednesday. The indirect effects of the current trade policy, and especially a potentially looming full-blown trade war, are likely to be greater for most companies than the direct effects, but in this compilation, we outline the potential effects of US import duties on various companies and sectors. This is our best estimate of the current impact, but the situation is evolving and uncertainty is now very high.

OptomedRevenio GroupDetection TechnologyNokiaTelesteRapala VMCWärtsiläVaisalaFiskarsHarviaMetsoKalmarGlastonPonsseKoneKonecranesRobitValmetRauteMetsä BoardStora Enso
Regulatory press release4/1/2025, 6:00 AM

Optomed Oyj: NOTICE OF THE ANNUAL GENERAL MEETING OF OPTOMED PLC

Optomed
Regulatory press release2/27/2025, 7:00 AM

Optomed Oyj: Optomed Annual Report 2024 published

Optomed
Press release2/14/2025, 8:48 AM

Redeye: Optomed Q4 - Quarter in line with expectations

Optomed
Regulatory press release2/13/2025, 7:00 AM

Optomed Oyj: Optomed Plc: Financial Statements Bulletin, January - December 2024

Optomed
Regulatory press release1/31/2025, 7:00 AM

Optomed Oyj: Proposal of Optomed's Nomination Board

Optomed
Life Science Companies as Investments | Life Science Night Dec. 2, 2024
Video12/2/2024, 2:00 PM

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia TechnologiesBBS-Bioactive Bone SubstitutesBioretecBiohitFaron PharmaceuticalsModulightNexstimOrionBittiumDetection TechnologyOptomedRevenio GroupNightingale HealthHerantis PharmaNanoform Finland
Regulatory press release11/14/2024, 9:00 AM

Optomed Oyj: Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings

Optomed
Regulatory press release11/13/2024, 9:00 AM

Optomed Oyj: Share subscriptions based on stock options 2018C

Optomed
Regulatory press release11/11/2024, 7:00 PM

Optomed Oyj: Inside information, profit warning: Optomed receives a large order in the US and increases its full year outlook

Optomed
Press release11/8/2024, 12:26 PM

Redeye: Optomed Q3 - In line with the expectations

Optomed
Regulatory press release11/7/2024, 7:00 AM

Optomed Oyj: Optomed Plc: Interim Report, January - September 2024

Optomed
Regulatory press release9/30/2024, 5:40 AM

Optomed Oyj: Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings

Optomed
Regulatory press release9/25/2024, 5:00 PM

Optomed Oyj: Inside information, profit warning: Optomed decreases its full year outlook

Optomed
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.